Pancreatic cancer is known as the silent killer for a reason. By the time symptoms like persistent stomach pain, weight loss, or jaundice show, the disease has typically advanced too far for surgery to be effective. For decades, doctors have attempted to detect this cancer earlier using a blood marker called CA19-9, but the test has left severe blind spots, missing certain malignancies while falsely scaring patients with minor pancreatic diseases. 

Now, experts at the University of Pennsylvania believe they have discovered a technique to finally close those gaps.

In a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), researchers led by Professor Kenneth S. Zaret report that adding two new blood proteins—ANPEP and PIGR—to existing markers could make pancreatic cancer screening far more reliable, particularly in the early stages. 

Why current exams fall short?

Pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 95% of all pancreatic cancers. If caught early and localised, the five-year survival rate is roughly 44%. The survival rate drops to a pitiful 3% once it spreads. 

The challenge is detection. CA19-9, the most common blood marker, is far from perfect. It can increase due to non-cancerous illnesses like pancreatitis, and some people make very little of it—even if they have cancer. 

"CA19-9 is widely used to monitor diagnosed pancreatic cancer but isn't recommended as a standalone screening test," Zaret told the newspaper. "Some people with pancreatic cancer may have low levels, while benign conditions can raise it." 

The missing puzzle parts 

Instead of just looking for more signals, Dr. Zaret's team looked for the specific signals that the current test misses. They analyzed blood samples from 672 people, including cancer patients and healthy individuals.

They found two specific proteins that showed up consistently in patients with early-stage cancer, but not in those with harmless stomach issues.

To put it simply, the current test is like a smoke alarm that goes off when you burn toast but stays silent during a real fire. The new proteins act as smarter sensors, helping doctors tell the difference between harmless "smoke" and a deadly fire.

What the evidence shows?

The four-biomarker panel (ANPEP, PIGR, CA19-9, and THBS2) diagnosed over 92% of pancreatic tumours at all stages. Importantly, it was substantially better at distinguishing early cancer from benign pancreatic illness, with a high accuracy score (AUC 0.87). 

This is an important distinction. A screening test that detects too many harmless illnesses cannot be extensively used because it produces undue anxiety and expensive follow-up scans. 

"Our goal was to look for biomarkers in the blood that appear in early-stage PDAC patients, so we could catch the disease early," Zaret told me. 

The goal is to buy time, not to offer a cure. 

The researchers are eager to emphasise that this is not a cure. Instead, it is a technique to gain time, something pancreatic cancer patients are frequently denied. 

If proven in bigger, real-time investigations, the test could help doctors decide which high-risk patients should be imaged, potentially detecting cancers while surgery is still possible. 

"With the addition of ANPEP and PIGR, the panel helps to overcome known limitations associated with CA19-9 and THBS2 testing," according to Zaret. "It could therefore reduce the number of missed cancer cases while keeping false positives low." 

What happens next? 

The study has limitations. It examined stored samples rather than assessing people prospectively, and it excluded high-risk categories such as those with a family history of pancreatic cancer or newly diagnosed diabetes. 

Nonetheless, analysts think it provides a clear direction. Closing the gaps in blood testing could be a critical step towards faster, life-saving treatment for a malignancy almost always diagnosed late.